Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant

Irreversible Bruton tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib have demonstrated remarkable clinical responses in multiple B-cell malignancies. Acquired resistance has been identified in a sub-population of patients in which mutations affecting BTK predominantly substitute cystein...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamasy, A, Wang, Q, Blomberg, K E M, Mohammad, D K, Yu, L, Vihinen, M, Berglöf, A, Smith, C I E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220130/
https://www.ncbi.nlm.nih.gov/pubmed/27282255
http://dx.doi.org/10.1038/leu.2016.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220130/
https://www.ncbi.nlm.nih.gov/pubmed/27282255
http://dx.doi.org/10.1038/leu.2016.153

Ejemplares similares